3SBio Inc. (HKG:1530)
Hong Kong · Delayed Price · Currency is HKD 23.00
-0.04 (-0.17%)
At close: Feb 3, 2026
3SBio Revenue
3SBio had revenue of 4.36B CNY in the half year ending June 30, 2025, with 15.11% growth. This brings the company's revenue in the last twelve months to 9.07B, up 7.75% year-over-year. In the year 2024, 3SBio had annual revenue of 9.11B with 16.53% growth.
Revenue (ttm)
9.07B CNY
Revenue Growth
+7.75%
P/S Ratio
5.79
Revenue / Employee
1.45M CNY
Employees
6,268
Market Cap
57.55B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.11B | 1.29B | 16.53% |
| Dec 31, 2023 | 7.82B | 950.20M | 13.84% |
| Dec 31, 2022 | 6.87B | 483.73M | 7.58% |
| Dec 31, 2021 | 6.38B | 794.37M | 14.22% |
| Dec 31, 2020 | 5.59B | 269.55M | 5.07% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sino Biopharmaceutical | 33.49B |
| Innovent Biologics | 12.52B |
| Genscript Biotech | 6.50B |
| Shanghai Henlius Biotech | 6.35B |
| Akeso | 2.75B |
| Shanghai Junshi Biosciences | 2.71B |
| RemeGen | 2.43B |
| Duality Biotherapeutics | 2.38B |
3SBio News
- 7 weeks ago - 3SBio Sells Shares, Divests Subsidiary To Boost Capital - Benzinga
- 2 months ago - China’s 3SBio seeks US$400 million in Hong Kong to boost drug pipeline - South China Morning Post
- 2 months ago - 3SBio spin-off Mandi banks on hair-loss and weight-loss drugs in Hong Kong IPO - South China Morning Post
- 3 months ago - Innovent's License Deal Fails To Excite investors - Benzinga
- 6 months ago - Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug - South China Morning Post
- 8 months ago - Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma - Benzinga
- 9 months ago - Pfizer Thinks Bigger With 3SBio Deal - Seeking Alpha
- 9 months ago - Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China - Investopedia